Even though the proportion of patients with optimal medical HF treatment will increase in patients with HFmrEF due to the upgrade of SGLT2 inhibitors in the revised European HF guidelines in 2023 [45], further studies are needed concerning the use of ARNI in patients with HFmrEF. The gene discussed is SLC5A2; the disease is hydrops fetalis.